A groundbreaking convergence of medical fields is happening, where research has revealed overlaps in diseases once considered distinct. Understanding how these disease mechanisms interrelate opens a new realm of scientific innovation, potentially leading to new treatments for various neurological conditions.
The Brain: Epicenter of Identity
The brain is the core of one’s identity, forming the unique sense of “self” for all humankind. Neurological diseases can disrupt this sense of self, causing life-altering impacts. Despite the evolving understanding of these diseases presenting challenges, it also sparks discoveries that uncover further mysteries about the human brain, offering immense promise for those affected.
Embracing Challenges for Therapeutic Innovation
We embrace these challenges, pushing the boundaries of clinical possibility to develop therapies as unique as the minds we aim to heal. This involves a thorough examination of neurological diseases, understanding the connections—from bodily processes to mental impacts. Our approach addresses the full spectrum of neuroinflammatory and neurodegenerative diseases by combining our expertise in immunoscience and neurology, establishing us as leaders in neuroimmunology.
Innovation in Neurology: A Complex Endeavor
Guided by science, our innovation in neurology requires deep expertise across complex diseases. Advanced technology and imaging techniques are crucial for conducting innovative clinical trials aimed at discovering new treatments for neurological diseases with substantial unmet needs. Additionally, innovative partnerships are essential to breaking new ground in this field.
Convergence of Fields: Rethinking Neurological and Immunological Diseases
Historically, neurological diseases involving the central nervous system and immunological conditions targeting the immune system were considered distinct. However, current research shows overlaps within these complex diseases, revealing common threads connecting the nervous and immune systems. There is substantial evidence of inflammatory processes in neurodegenerative conditions and neurodegenerative aspects in inflammatory conditions. Understanding these interactions could lead to numerous new possibilities.
Unlocking the Science of Neuroimmunology
Over the past 20 years, significant progress has been made in understanding neurological diseases such as multiple sclerosis (MS), where relapses are now well managed. However, disease-associated disability continues to progress, indicating that factors beyond relapses drive the destructive nature of MS. New research has identified a smoldering inflammatory process within the brain that contributes to disability, occurring early in the disease with no proven therapies available.
We believe neuroimmunology holds the key to introducing new treatments to combat disability progression, addressing the greatest unmet need in MS. Beyond MS, we are exploring new treatments for other neuroimmunological diseases, such as chronic inflammatory demyelinating polyneuropathy (CIDP), where the immune system mistakenly attacks nerve fibers. Currently, neurologists have only one treatment option for CIDP, leaving many needs unmet.
Tackling Complex Neurological Conditions
Our expanding neurology pipeline focuses on areas of high unmet need. We believe neuroimmunology is just the beginning of transformational development. By continuing to follow the science, we aim to extend the advancements seen in MS to other neurological diseases like Parkinson’s, Alzheimer’s, and CIDP. As we learn more, we strive to develop better therapies, ultimately managing these diseases effectively.
Commitment to Neuroimmunology
At Sanofi, we are committed to delving deeper into neuroimmunology, protecting people through science so they can live for the moment, not for the disease.